Cygenics contract with DOD renewed
Wednesday, 16 February, 2005
Singapore-based Cygenics (ASX: CYN) has announced that the US Department of Defence had renewed its screening service contract with the company's US-based subsidiary Cytomatrix.
The renewal of the contract means that the company will receive the more than US$1 million remaining from the original contract which was valued at $1.684 million.
The DOD is using Cytomatrix's three-dimensional cell growth scaffold technology for the production of T cells that can be used to screen vaccine prototypes under development, allowing assessment of in vivo activity in an in vitro system.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
